Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study

Stefanie Binzer, Kyla A McKay, Philip Brenner, Jan Hillert, Ali Manouchehrinia, Stefanie Binzer, Kyla A McKay, Philip Brenner, Jan Hillert, Ali Manouchehrinia

Abstract

Objective: Depression is common in multiple sclerosis (MS), but its impact on disability worsening has not yet been determined. We explored the risk of disability worsening associated with depression in a nationwide longitudinal cohort.

Methods: This retrospective cohort study used linked data from 3 Swedish nationwide registries: the MS Register, National Patient Register, and Prescribed Drug Register. Two incident cohorts were developed: cohort 1 included all registered cases of MS in the MS Registry (2001-2014) with depression defined as ≥1 ICD-10 code for depression; and cohort 2 comprised all cases of MS in the MS Registry (2005-2014) with depression defined as ≥1 prescription filled for an antidepressant. Cox regression models were used to compare the risk of reaching sustained disability milestone scores of 3.0, 4.0, and 6.0 on the Expanded Disability Status Scale (EDSS) between persons with MS with and without depression.

Results: Cohort 1 included 5,875 cases; 502 (8.5%) had depression. Cohort 2 had 3,817 cases; 1,289 (33.8%) were prescribed an antidepressant. Persons with depression were at a significantly higher risk of reaching sustained EDSS scores of 3.0, 4.0, and 6.0, with hazard ratios of 1.50 (95% confidence interval [CI] 1.20-1.87), 1.79 (95% CI 1.40-2.29), and 1.89 (95% CI 1.38-2.57), respectively. A similar increased risk among persons exposed to antidepressants was observed, with hazard ratios of 1.37 (95% CI 1.18-1.60), 1.93 (95% CI 1.61-2.31), and 1.86 (95% CI 1.45-2.40) for sustained EDSS scores of 3.0, 4.0, and 6.0, respectively.

Conclusion: Persons with MS and comorbid depression had a significantly increased risk of disability worsening. This finding highlights the need for early recognition and appropriate treatment of depression in persons with MS.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Flowchart of data collection in…
Figure 1. Flowchart of data collection in Swedish national registries
MS = multiple sclerosis.
Figure 2. Kaplan-Meier estimates of age at…
Figure 2. Kaplan-Meier estimates of age at EDSS score milestones
Kaplan-Meier estimates of age at Expanded Disability Status Scale (EDSS) score milestones 3.0 (A and B), 4.0 (C and D), and 6.0 (E and F) stratified by depression diagnosis (A, C, and E) and exposure to antidepressants (B, D, and F).

References

    1. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015;14:263–273.
    1. Hempel S, Graham GD, Fu N, et al. . A systematic review of modifiable risk factors in the progression of multiple sclerosis. Mult Scler 2017;23:525–533.
    1. Manouchehrinia A, Beiki O, Hillert J. Clinical course of multiple sclerosis: a nationwide cohort study. Mult Scler 2017;23:1488–1495.
    1. Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. . Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler 2017;23:1233–1240.
    1. Ramanujam R, Hedström AK, Manouchehrinia A, et al. . Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 2015;72:1117–1123.
    1. Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol 2017;13:375–382.
    1. McKay KA, Jahanfar S, Duggan T, Tkachuk S, Tremlett H. Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review. Neurotoxicology 2017;61:189–212.
    1. Johansson V, Lundholm C, Hillert J, et al. . Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort. Mult Scler 2014;20:1881–1891.
    1. Hoang H, Laursen B, Stenager EN, Stenager E. Psychiatric co-morbidity in multiple sclerosis: the risk of depression and anxiety before and after MS diagnosis. Mult Scler 2016;22:347–353.
    1. Boeschoten RE, Braamse AMJ, Beekman ATF, et al. . Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 2017;372:331–341.
    1. Marrie RA, Fisk JD, Tremlett H, et al. . Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology 2015;85:1972–1979.
    1. Marrie RA, Walld R, Bolton JM, et al. . Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. Gen Hosp Psychiatry 2018;53:65–72.
    1. Tinghög P, Björkenstam C, Carstensen J, et al. . Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study. BMC Neurol 2014;14:117.
    1. Brenner P, Alexanderson K, Björkenstam C, et al. . Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study. PLoS One 2014;9:e104165.
    1. McKay KA, Tremlett H, Fisk JD, et al. . Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology 2018;90:e1316–e1323.
    1. Koch M, Uyttenboogaart M, van Harten A, Heerings M, De Keyser J. Fatigue, depression and progression in multiple sclerosis. Mult Scler 2008;14:815–822.
    1. Hillert J, Stawiarz L. The Swedish MS registry: clinical support tool and scientific resource. Acta Neurol Scand 2015;132:11–19.
    1. Polman CH, Reingold SC, Banwell B, et al. . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
    1. World Health Organisation. World Health Organisation Collaborating Centre for Drug Statistics methodology [online]. Available at: . Accessed May 15, 2019.
    1. Marrie RA, Fisk JD, Yu BN, et al. . Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol 2013;13:16.
    1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–911.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
    1. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2017. Available at: . Accessed January 15, 2019
    1. Patten SB, Metz LM. Hopelessness ratings in relapsing-remitting and secondary progressive multiple sclerosis. Int J Psychiatry Med 2002;32:155–165.
    1. McKay KA, Tremlett H, Fisk JD, et al. . Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: a prospective multisite study. Mult Scler 2016;22:685–693.
    1. Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010;33:219–227.
    1. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89–100.
    1. Kangas JL, Baldwin AS, Rosenfield D, Smits JA, Rethorst CD. Examining the moderating effect of depressive symptoms on the relation between exercise and self-efficacy during the initiation of regular exercise. Health Psychol 2015;34:556–565.
    1. Dalgas U. Exercise therapy in multiple sclerosis and its effects on function and the brain. Neurodegener Dis Manag 2017;7:35–40.
    1. Duchovskiene N, Mickeviciene D, Jurkeviciene G, Dirziuviene B, Balnyte R. Factors associated with adherence to disease modifying therapy in multiple sclerosis: an observational survey from a referral center in Lithuania. Mult Scler Relat Disord 2017;13:107–111.
    1. McKay KA, Tremlett H, Patten SB, et al. . Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study. Mult Scler 2017;23:588–596.
    1. Czéh B, Nagy SA. Clinical findings documenting cellular and molecular abnormalities of glia in depressive disorders. Front Mol Neurosci 2018;11:56.
    1. Kato TA, Myint AM, Steiner J. Editorial: minding glial cells in the novel understandings of mental illness. Front Cell Neurosci 2017;11:48.
    1. Zhou F, Zhuang Y, Wang L, et al. . Disconnection of the hippocampus and amygdala associated with lesion load in relapsing-remitting multiple sclerosis: a structural and functional connectivity study. Neuropsychiatr Dis Treat 2015;11:1749–1765.
    1. Kern KC, Gold SM, Lee B, et al. . Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis. Neuroimage Clin 2015;8:440–447.
    1. Rocca MA, Pravatà E, Valsasina P, et al. . Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. Hum Brain Mapp 2015;36:5051–5063.
    1. Shen X, Reus LM, Cox SR, et al. . Subcortical volume and white matter integrity abnormalities in major depressive disorder: findings from UK Biobank imaging data. Sci Rep 2017;7:5547.
    1. Gentile A, De Vito F, Fresegna D, et al. . Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis. Front Cell Neurosci 2015;9:243.
    1. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012;26:469–479.
    1. Khodanovich M, Kisel A, Kudabaeva M, et al. . Effects of fluoxetine on hippocampal neurogenesis and neuroprotection in the model of global cerebral ischemia in rats. Int J Mol Sci 2018;19:E162.
    1. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007;18:391–418.
    1. Kelly JR, Cosgrove M, Judd C, Scott K, Loughlin AM, O'Keane V. Mood matters: a national survey on attitudes to depression. Ir J Med Sci Epub 2019 April 2.
    1. Patten SB, Burton JM, Fiest KM, et al. . Validity of four screening scales for major depression in MS. Mult Scler 2015;21:1064–1071.
    1. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol 2014;10:507–517.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera